Applied Therapeutics Inc. (APLT) Announces Offering of 3M Shares of Common Stock
- Wall St. opens lower as Netflix slides, virus cases rise
- Netflix (NFLX) Plunges Following Q1 Sub Miss, But One Analyst Sees Chance to Turn Bullish
- Oil prices drop as India's COVID-19 surge dents demand outlook
- Intuitive Surgical (ISRG) Q1 Beat Prompts Two Street Upgrades
- Dollar firm as COVID-19 resurgence hits reflation trades
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of 3,000,000 shares of its common stock, par value $0.0001 per share, in an underwritten registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to 450,000 additional shares of its common stock.
The Company intends to use the net proceeds from this offering, together with its existing cash, to advance clinical and preclinical development of its product candidates, prepare for commercialization and other general corporate purposes.
Goldman Sachs & Co. LLC, Cowen and UBS Investment Bank are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the final size or terms of the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 04/21: (OCGN) (WBT) (ISRG) Higher; (DGLY) (NFLX) (ROKU) Lower (more...)
- UBS Upgrades EMS-Chemie Holding AG (EMSN:SW) to Neutral
- UiPath Inc. (PATH) Prices 23.89M Share IPO at $56/Sh
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesUBS, Goldman Sachs, Cowen & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!